Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors

Effect of NF-κB inhibition on chemoresistance in biliary–pancreatic cancer

(2015) Tadashi Uwagawa et al.   SURGERY TODAY

Poor prognosis of common-type invasive ductal carcinomas that originate in the branching pancreatic duct

(2014) Masataka Ando et al.   SURGERY TODAY

Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial

(2013) Fuyuhiko Motoi et al.   ANNALS OF SURGICAL ONCOLOGY

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

(2013) Hideki Ueno et al.   JOURNAL OF CLINICAL ONCOLOGY

Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?

(2013) Kaitlyn J. Kelly et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies

(2011) Angelo Andriulli et al.   ANNALS OF SURGICAL ONCOLOGY

Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer

(2011) H. Ueno et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas

(2011) Yuji Nimura et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Impact of Histological Response After Neoadjuvant Chemoradiotherapy on Recurrence-Free Survival in UICC-T3 Pancreatic Adenocarcinoma But Not in UICC-T4

(2011) Yasuhiro Murata et al.   PANCREAS

Defining Venous Involvement in Borderline Resectable Pancreatic Cancer

(2010) Yun Shin Chun et al.   ANNALS OF SURGICAL ONCOLOGY

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer

(2010) Klaus Sahora et al.   SURGERY

A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database

(2010) May Piperdi et al.   HPB

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

(2010) Sonja Gillen et al.   PLOS MEDICINE

Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review

(2009) R. Le Scodan et al.   ANNALS OF ONCOLOGY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Does the Mechanism of Lymph Node Invasion Affect Survival in Patients with Pancreatic Ductal Adenocarcinoma?

(2009) Ioannis T. Konstantinidis et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer

(2009) Sohei Satoi et al.   PANCREAS

Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head

(2008) Stefan Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Hospital Volume on Margin Status after Pancreaticoduodenectomy for Cancer

(2008) Karl Y. Bilimoria et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

(2008) Matthew H.G. Katz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS